NGM Biopharmaceuticals Inc. (NGM) has a couple of clinical trial catalysts to watch in the coming months. Topline data from a phase II trial of NGM621 in patients with geographic atrophy, dubbed CATALINA is expected in the second half of this year.
from RTT - Earnings https://ift.tt/ofFl2kx
via IFTTT
No comments:
Post a Comment